
Adipotide (FTPP) is a peptidomimetic that targets blood vessels feeding white adipose tissue, causing programmed cell death in fat cells. In primate studies, it produced rapid weight loss by cutting off blood supply to fat deposits. It remains experimental.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
How Adipotide Works
Targets prohibitin on blood vessels supplying white adipose tissue, potentially disrupting blood supply to fat cells and triggering apoptosis.
Adipotide FAQ
What is ADIPOTIDE?
Adipotide is a research peptide studied for its unique mechanism of targeting and potentially eliminating fat cells through apoptosis (programmed cell death).
How does ADIPOTIDE work?
Targets prohibitin on blood vessels supplying white adipose tissue, potentially disrupting blood supply to fat cells and triggering apoptosis.
Is ADIPOTIDE legal to buy?
ADIPOTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy ADIPOTIDE?
ADIPOTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does ADIPOTIDE belong to?
ADIPOTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of ADIPOTIDE?
ADIPOTIDE has been studied for: Targeted fat reduction, Adipose tissue targeting. Targeted fat cell apoptosis; niche research peptide.
Adipotide Compound Data
Adipotide News
Adipotide (FTPP) Peptide as a Tool for Research in Adipose Cell Research and Metabolic Studies - Racine County Eye
Racine County Eye · 8 months ago
Adipotide and the Architecture of Selective Adipose Targeting: A research-focused exploration - Jamaica Observer
Jamaica Observer · 8 days ago
Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. · 168 months ago
A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication - ScienceDirect.com
ScienceDirect.com · 152 months ago
A more selective attack - Revista Pesquisa Fapesp
Revista Pesquisa Fapesp · 72 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Adipotide with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Adipotide.
Take the Quiz →